Esperion Therapeutics Operating Cycle Over Time
| ESPR Stock | USD 3.43 0.03 0.88% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Esperion Therapeutics Performance and Esperion Therapeutics Correlation. Can Biotechnology industry sustain growth momentum? Does Esperion have expansion opportunities? Factors like these will boost the valuation of Esperion Therapeutics. Projected growth potential of Esperion fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Esperion Therapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (0.54) | Revenue Per Share | Quarterly Revenue Growth 0.691 | Return On Assets | Return On Equity |
The market value of Esperion Therapeutics is measured differently than its book value, which is the value of Esperion that is recorded on the company's balance sheet. Investors also form their own opinion of Esperion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Esperion Therapeutics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Esperion Therapeutics' market value can be influenced by many factors that don't directly affect Esperion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Esperion Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Esperion Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Esperion Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Cycle Analysis
Compare Esperion Therapeutics and related stocks such as SNDL Inc, SIGA Technologies, and Aquestive Therapeutics Operating Cycle Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SNDL | 24.5556 | 24.5556 | 24.5556 | 24.5556 | 24.5556 | 24.5556 | 24.5556 | 24.5556 | 1.2 K | 1.2 K | 191 | 261 | 95.3849 | 76.6376 | 80.4377 | 92.5 | 87.88 |
| SIGA | 104 | 75.6371 | 393 | 605 | 699 | 510 | 562 | 119 | 11.3017 | 290 | 297 | 657 | 1.5 K | 1.4 K | 634 | 570 | 599 |
| AQST | 141 | 141 | 141 | 141 | 141 | 141 | 141 | 108 | 130 | 142 | 125 | 185 | 145 | 180 | 170 | 153 | 118 |
| EBS | 2.1 K | 239 | 157 | 107 | 170 | 219 | 222 | 283 | 285 | 221 | 210 | 186 | 251 | 241 | 224 | 258 | 344 |
| VTYX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| CRVS | 1.8 K | 1.8 K | 1.8 K | 1.8 K | 1.8 K | 1.8 K | (369) | (369) | (259) | (259) | (259) | (259) | (259) | (259) | (259) | (298) | (283) |
| OLMA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| OFIX | 225 | 358 | 456 | 388 | 277 | 298 | 315 | 372 | 353 | 368 | 368 | 325 | 362 | 374 | 334 | 301 | 260 |
| ABSI | 39.335 | 39.335 | 39.335 | 39.335 | 39.335 | 39.335 | 39.335 | 39.335 | 39.335 | 39.335 | 122 | 195 | 192 | 140 | 140 | 126 | 110 |
| RGNX | 65.2407 | 65.2407 | 65.2407 | 65.2407 | 112 | 350 | 758 | 1.2 K | 231 | 395 | 209 | 25.1734 | 98.0854 | 107 | 94.4695 | 109 | 103 |
Esperion Therapeutics and related stocks such as SNDL Inc, SIGA Technologies, and Aquestive Therapeutics Operating Cycle description
My Equities
My Current Equities and Potential Positions
| Esperion Therapeutics | ESPR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 3891 Ranchero Drive, |
| Exchange | NASDAQ Exchange |
USD 3.43
Additional Tools for Esperion Stock Analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.